MiRNA-based Therapeutics for Lung Cancer

被引：70
|
作者：
Wu, Miaowei [1 ]
Wang, Guosheng [2 ]
Tian, Wei [1 ]
Deng, Yongchuan [1 ]
Xu, Yibing [2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Surg Oncol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China
[2] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou 310029, Zhejiang, Peoples R China
来源：
CURRENT PHARMACEUTICAL DESIGN | 2017年 / 23卷 / 39期
基金：
中国国家自然科学基金;
关键词：
miRNA; oncogene; tumor suppressor; drug resistance; lung cancer; therapy; TUMOR-SUPPRESSOR; GEFITINIB-RESISTANCE; MICRORNA EXPRESSION; PROGNOSTIC-SIGNIFICANCE; MESENCHYMAL TRANSITION; CELLS; GROWTH; LET-7; PROLIFERATION; INVASION;
D O I：
10.2174/1381612823666170714151715
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: miRNA, a small non-coding RNA molecule containing about 22 nucleotides, functions in RNA silencing and post-transcriptional regulation of gene expression. With these qualities, miRNAs modulate multiple signaling pathways involved in cancer development, such as cellular proliferation, apoptosis, and migration. Methods: The goal of this review is to discuss possible miRNAs-based therapeutic strategies, through defining performance of miRNAs in carcinogenesis, in particular in lung cancer. Results: miRNA, a non-coding RNA, is divided into two main types: tumor suppressor miRNAs and oncogenic miRNAs. In addition, special processed miRNAs can be an assistant therapeutic tool. Conclusion: In order to develope antitumor therapy, miRNAs-based therapeutic strategies are worth of deeper studies. In this process, the stability, effectiveness, and side effects should be considered.
引用
收藏
页码：5989 / 5996
页数：8
相关论文
共 50 条
  • [1] miRNA-Based Therapeutics in Breast Cancer: A Systematic Review
    Grimaldi, Anna Maria
    Salvatore, Marco
    Incoronato, Mariarosaria
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer
    Wong, Jun Sheng
    Cheah, Yoke Kqueen
    [J]. NON-CODING RNA, 2020, 6 (03) : 1 - 39
  • [3] MiRNA-based Therapeutic Strategy in Lung Cancer
    Li, Guang
    Fang, Jing
    Wang, Ying
    Wang, Hu
    Sun, Cheng-Cao
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 6011 - 6018
  • [4] miRNA-Based Therapeutics for Heart Failure Why Not?
    Hulot, Jean-Sebastien
    Masurkar, Nihar
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (15) : 1801 - 1803
  • [5] MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?
    Yang, Han
    Liu, Yufang
    Chen, Longqing
    Zhao, Juanjuan
    Guo, Mengmeng
    Zhao, Xu
    Wen, Zhenke
    He, Zhixu
    Chen, Chao
    Xu, Lin
    [J]. BIOMOLECULES, 2023, 13 (06)
  • [6] siRNA- and miRNA-based therapeutics for liver fibrosis
    Zhao, Zhen
    Lin, Chien-Yu
    Cheng, Kun
    [J]. TRANSLATIONAL RESEARCH, 2019, 214 : 17 - 29
  • [7] miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
    Bayraktar, Recep
    Van Roosbroeck, Katrien
    [J]. CANCER AND METASTASIS REVIEWS, 2018, 37 (01) : 33 - 44
  • [8] Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives
    Bravo-Vazquez, Luis Alberto
    Mendez-Garcia, Andrea
    Rodriguez, Alma L. L.
    Sahare, Padmavati
    Pathak, Surajit
    Banerjee, Antara
    Duttaroy, Asim K. K.
    Paul, Sujay
    [J]. FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
  • [9] miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
    Recep Bayraktar
    Katrien Van Roosbroeck
    [J]. Cancer and Metastasis Reviews, 2018, 37 : 33 - 44
  • [10] Towards MiRNA Based Therapeutics for Lung Cancer
    Zhou, Qun
    Sun, Cheng-Cao
    Li, De-Jia
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (39) : 5971 - 5972
12345